Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments to Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting

This site contains about 63,386 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   100   200   300   400   500   600   700   810   820   830   840   850   860   870   880   890   903   904   905   906   907   908   909   910   911   912   913   914   915   916   917   918   919   920   921   922   923   924   925   926   927   928   929   930   931   932   940   950   960   970   980   990   1,000   1,010   1,100   1,200   1,300   1,400   1,500   1,600   1,700   1,800   1,900   2,000   2,113 

2013/5/8
Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments
MORRIS PLAINS, N.J., May 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the third quarter ended March 31, 2013.
View more Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments analysis
Sign-up for Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments investment picks
2013/5/7
Immunomedics Announces Three New Patent Awards
MORRIS PLAINS, N.J., May 7, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it has received notice that its patent application for "Delivery system for cytotoxic drugs by bispecific antibody pretargeting," will issue as US patent No.
View more Immunomedics Announces Three New Patent Awards analysis
Sign-up for Immunomedics Announces Three New Patent Awards investment picks
2013/4/8
Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy
-- Preclinical Study Presented at 2013 Annual Meeting of the American Association for Cancer Research (AACR) -- WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) --  Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the creation of a new class of antibody-cytokine conjugates using the Company's patented DOCK-AND-LOCK™ (DNL™) platform technology.
View more Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy analysis
Sign-up for Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy investment picks
2013/4/10
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors
WASHINGTON, April 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the development of novel T-cell redirecting agents made as DOCK-AND-LOCK™ (DNL™) complexes by tethering a single-chain variable fragment (scFv) that binds to CD3 on T cells to different antibody fragments that target tumor antigens.
View more Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors analysis
Sign-up for Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors investment picks
2013/2/22
Immunomedics Prices $14.0 Million Public Offering of Common Stock
MORRIS PLAINS, N.J., Feb.
View more Immunomedics Prices $14.0 Million Public Offering of Common Stock analysis
Sign-up for Immunomedics Prices $14.0 Million Public Offering of Common Stock investment picks
2013/4/9
Immunomedics Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer
WASHINGTON, April 9, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that its proprietary antibody-drug conjugate (ADC), labetuzumab-SN-38, appears to be safe and reasonably well tolerated within a clinically effective dosage range in patients with advanced colorectal cancer.
View more Immunomedics Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer analysis
Sign-up for Immunomedics Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer investment picks
2013/4/1
Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities
MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, reached a settlement on March 27, 2013, in its previously disclosed arbitration proceeding before the Financial Industry Regulatory Authority against a broker-dealer relating to the Company's prior investment in certain securities.
View more Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities analysis
Sign-up for Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities investment picks
2013/2/25
Immunomedics to Present at Cowen and Company 33rd Annual Health Care Conference
MORRIS PLAINS, N.J., Feb.
View more Immunomedics to Present at Cowen and Company 33rd Annual Health Care Conference analysis
Sign-up for Immunomedics to Present at Cowen and Company 33rd Annual Health Care Conference investment picks
2013/4/1
Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings
Immunomedics Inc. (IMMU) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.
View more Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings analysis
Sign-up for Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings investment picks
2013/3/7
Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV Treatment
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=994141&ProfileId=051205&sourceType=1 MONROVIA, CA --
View more Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV Treatment analysis
Sign-up for Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV Treatment investment picks
2013/3/12
Immunotech Founder & Chief Scientific Officer Harry Zhabilov Comments on Recent HIV Baby Cure Medicine
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=995739&ProfileId=051205&sourceType=1 MONROVIA, CA --
View more Immunotech Founder & Chief Scientific Officer Harry Zhabilov Comments on Recent HIV Baby Cure Medicine analysis
Sign-up for Immunotech Founder & Chief Scientific Officer Harry Zhabilov Comments on Recent HIV Baby Cure Medicine investment picks
2013/4/15
Immunotech Laboraties Appoints New VP of Business Development
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1007020&ProfileId=051205&sourceType=1 MONROVIA, CA --
View more Immunotech Laboraties Appoints New VP of Business Development analysis
Sign-up for Immunotech Laboraties Appoints New VP of Business Development investment picks
2013/3/18
Immunotech Laboraties in Discussions for Pre-"IND" Testing of Aids-HIV "IPF" Treatment in the USA
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=997553&ProfileId=051205&sourceType=1 MONROVIA, CA --
View more Immunotech Laboraties in Discussions for Pre-"IND" Testing of Aids-HIV "IPF" Treatment in the USA analysis
Sign-up for Immunotech Laboraties in Discussions for Pre-"IND" Testing of Aids-HIV "IPF" Treatment in the USA investment picks
2013/4/8
Immunotech Laboraties Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1004751&ProfileId=051205&sourceType=1 MONROVIA, CA --
View more Immunotech Laboraties Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status analysis
Sign-up for Immunotech Laboraties Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status investment picks
2013/4/26
Immunotech Laboratories Begins Regulatory Process With US Food & Drug Administration
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1011105&ProfileId=051205&sourceType=1 MONROVIA, CA --
View more Immunotech Laboratories Begins Regulatory Process With US Food & Drug Administration analysis
Sign-up for Immunotech Laboratories Begins Regulatory Process With US Food & Drug Administration investment picks
2013/2/19
Immunotech Laboratories, Inc. Announces Analyst Report Issued by Market Advisors, Inc.
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=987021&ProfileId=051205&sourceType=1 PASADENA, CA --
View more Immunotech Laboratories, Inc. Announces Analyst Report Issued by Market Advisors, Inc. analysis
Sign-up for Immunotech Laboratories, Inc. Announces Analyst Report Issued by Market Advisors, Inc. investment picks
2013/3/1
Immunotech Relocates to New Research & Development Laboratory Facility
http://media.marketwire.com/attachments/201302/132712_IMMBLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=991882&ProfileId=051205&sourceType=1 PASADENA, CA --
View more Immunotech Relocates to New Research & Development Laboratory Facility analysis
Sign-up for Immunotech Relocates to New Research & Development Laboratory Facility investment picks
2013/4/24
Impairment Loss Erases Vornado's Toys 'R' Us 4th-Quarter Income
Vornado Realty Trust (VNO) disclosed income from its share of Toys "R" Us Inc.'s fourth-quarter results would be erased by a corresponding impairment loss.
View more Impairment Loss Erases Vornado's Toys 'R' Us 4th-Quarter Income analysis
Sign-up for Impairment Loss Erases Vornado's Toys 'R' Us 4th-Quarter Income investment picks
2013/2/8
Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR®
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. (collectively Shire) relating to supply of its authorized generic Adderall XR® under the parties’ License and Distribution Agreement that was signed in January 2006.
View more Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR® analysis
Sign-up for Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR® investment picks
2013/5/2
IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
View more IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc. analysis
Sign-up for IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc. investment picks
2013/5/17
Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (AstraZeneca). Zomig® is indicated for the treatment of migraine headaches in adults.
View more Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S. analysis
Sign-up for Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S. investment picks
2013/5/1
Impax Laboratories Reports First Quarter 2013 Results
Impax Laboratories, Inc. (NASDAQ: IPXL) today reported first quarter 2013 adjusted net income of $25.3 million or $0.37 per diluted share, compared to $35.8 million or $0.53 per diluted share in the first quarter 2012.
View more Impax Laboratories Reports First Quarter 2013 Results analysis
Sign-up for Impax Laboratories Reports First Quarter 2013 Results investment picks
2013/2/25
Impax Laboratories Reports Fourth Quarter and Full Year 2012 Results
Impax Laboratories, Inc. (NASDAQ: IPXL) today reported fourth quarter 2012 adjusted net income of $20.5 million or $0.30 per diluted share, compared to $21.9 million or $0.33 per diluted share in the fourth quarter 2011.
View more Impax Laboratories Reports Fourth Quarter and Full Year 2012 Results analysis
Sign-up for Impax Laboratories Reports Fourth Quarter and Full Year 2012 Results investment picks
2013/4/3
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its first quarter 2013 financial results on Wednesday, May 1, 2013, after the close of the U.S. financial markets.
View more Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results analysis
Sign-up for Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results investment picks
2013/3/8
Impax Laboratories Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor, LLP announce an investigation into potential violations of federal securities laws by certain officers and directors of Impax Laboratories, Inc. (“Impax” or “Company”) (NasdaqGS: IPXL). If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com , or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607.
View more Impax Laboratories Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors analysis
Sign-up for Impax Laboratories Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
2013/5/10
Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, at 8:00 a.m. Pacific Standard Time.
View more Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference analysis
Sign-up for Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference investment picks
2013/3/1
Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Cowen & Company 33 rd Annual Health Care Conference on Wednesday, March 6, at 8:00 a.m. Eastern Standard Time.
View more Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference analysis
Sign-up for Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference investment picks
2013/3/14
Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders
SAN DIEGO and HUNTERSVILLE, N.C. , March 14, 2013 /PRNewswire/ --  Shareholder rights firm Robbins Arroyo LLP is investigating whether officers and directors of Impax Laboratories, Inc. (NASDAQ: IPXL) breached their fiduciary duties to shareholders by failing to correct the Company's inadequate quality controls and deficiencies in its manufacturing processes.
View more Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders analysis
Sign-up for Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders investment picks
2013/4/29
Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM)
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Impax and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the United States (U.S.) and Taiwan.
View more Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM) analysis
Sign-up for Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM) investment picks
2013/3/19
Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced the presentation of results from its RYTARY TM (IPX066) Phase III and open-label extension trials at the 65 th Annual Meeting of the American Academy of Neurology in San Diego, CA on March 18, 2013.
View more Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting analysis
Sign-up for Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments to Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.